357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

MLA

Cheryl Li, et al. “357 TAK-573, an Anti-CD38–attenuated Interferon Alpha (IFNα) Fusion Protein (Attenukine™), Has Demonstrated IFNα Receptor (IFNAR) Pathway Modulation in Patients with Relapsed/Refractory Multiple Myeloma.” Journal for ImmunoTherapy of Cancer, vol. 8, no. Suppl 3, Nov. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-SITC2020.0357.

APA

Cheryl Li, Lei Shen, Sabrina Collins, Adarsh Joshi, Subhasree Das, Kaveri Suryanarayan, Dean Bottino, Michael Curley, Dannie Wang, Michael Abadier, Ryan Larson, & Xavier Parot. (2020). 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma. Journal for ImmunoTherapy of Cancer, 8(Suppl 3). https://doi.org/10.1136/jitc-2020-SITC2020.0357

Chicago

Cheryl Li, Lei Shen, Sabrina Collins, Adarsh Joshi, Subhasree Das, Kaveri Suryanarayan, Dean Bottino, et al. 2020. “357 TAK-573, an Anti-CD38–attenuated Interferon Alpha (IFNα) Fusion Protein (Attenukine™), Has Demonstrated IFNα Receptor (IFNAR) Pathway Modulation in Patients with Relapsed/Refractory Multiple Myeloma.” Journal for ImmunoTherapy of Cancer 8 (Suppl 3). doi:10.1136/jitc-2020-SITC2020.0357.